Air
Products & services that promote respiration.
The Air brand pillar is a portfolio of products and services related to breathing, and the quality of air we breathe.
ASTHMA AND COPD
Chiesi Farmaceutici is fully committed to the care and improvement of the quality of life of people...
Care
Combines products and services that support the specialized care provided by medical professionals and over-the-counter products.
The Care brand pillar is our portfolio of products and services related to special care and consumer healthcare. It includes:
Neonatology -products for...
Rare
In February, 2020 Chiesi launched Chiesi Global Rare Diseases, a new business unit focused on research, development and commercialization of treatments and patient support services for rare and ultra-rare disorders.
The Global Rare Diseases unit works in collaboration with Chiesi Group to...
Manufacturing plants
Chiesi Farmaceutici has four production plants.
PARMA, ITALY
Our Parma plant is the strategic hub for the production and distribution of our products, serving as an international supply center with exports to over 80 countries.
Production capacity:
26 million packages...
About us
We are an international biopharmaceutical group, research-oriented, with over 85 years of experience. Our headquarters is located in Parma, but we export in more than 100 countries, with a direct presence in 31.
The Chiesi Group researches, develops and innovative therapeutic...
cookies
This is a document providing information regarding the use of cookies and other similar technologies on the website https://www.chiesi.com/ (hereinafter referred to as the "Site"). This notice is provided to the user/visitor in compliance with the European and the Italian legislation on the...
Mission and Values
Our aim is to be recognised as a research-focused international Group, able to develop and commercialise innovative pharmaceutical solutions to improve the quality of human life.
We wish to maintain a high quality entrepreneurial team characterised by self-confidence and a collaborative...
People care
People Care
Psychological and physical well-being workshop
Legal aid
Sick-bay service
Day of paid leave for fathers on the birth of a child
Summer Centres for children and young teenagers
Healthcare and welfare assistance
Paid leave for specialist visits
Influenza vaccine...
Accessibility
What is Accessibility?
The term web accessibility refers to the computer systems’ ability to deliver services and provide usable information, without discrimination, also to those in need of assistive technologies or special settings due to specific disabilities.
The...
Frequently asked questions
-
Pharmacovigilance
Chiesi Farmaceutici has a system of pharmacovigilance in order to assume liability for our products (whether marketed or under clinical development) and to take appropriate actions when necessary. We ensure that all information relevant to patient safety and the risk-benefit ratio of our products...
Who we are
Global Business and Corporate Development
Our Global Business and Corporate Development team drives strategic growth by identifying and executing mergers and acquisitions, partnerships, and alliances. Committed to strengthening the company’s market position, it focuses on driving...
GENERAL TERMS AND CONDITIONS OF USE AND ACCESS TO WEBSITE
TERMS OF SERVICE – CHIESI.COM
www.chiesi.com (the “Website”) is owned and operated by Chiesi Farmaceutici S.p.A., an Italian company with a registered office in Via Palermo 26/A, 43122 Parma, Italy (hereinafter referred to as “Chiesi”).
That is...
Privacy
PRIVACY NOTICE – CHIESI.COM Under Article 13 of Regulation (EU) 2016/679 on the protection of individuals regarding the processing of personal data (hereinafter "GDPR")
Dear User,
Thank you for visiting chiesi.com, the website of Chiesi Farmaceutici S.p.A. (hereinafter...
Research and Development
Innovation is the driving force behind every technologically advanced industry, but for the pharmaceutical industry it plays a vital role since it concerns the health and quality of life of patients. For Chiesi, Research and Development represents a true human and technological asset and, together...
Certification Notice
“Certified B Corporation” is a trademark licensed by B Lab, a private non-profit organization, to companies like ours that have successfully completed the B Impact Assessment (“BIA”) and therefore meet the requirements set by B Lab for social and...
Pipeline
R&D Pipeline: balanced with focus
Research and development programmes continue to progress year by year with a strong focus in four key areas: respiratory, neonatology, rare disease and special care.
RESPIRATORY AND NEONATOLOGY
Respiratory is a core area...
Work with Us
Work with Us
Our culture belongs to the brave and the curious. At Chiesi we focus on finding innovative solutions and embracing new challenges. Every choice we make is driven by the will to generate a positive impact both on our community and our planet
We firmly believe that...
TIPs
BE PREPARED
It’s very easy to be nervous before an interview, however experience will teach you that the more prepared you are, the less nervous you will be.
Young graduates and post graduates
-
Experienced Professionals
-
Primary care
RHEUMATIC AND MUSCULOSKELETAL DISEASES
RHEUMATOID ARTHRITIS
Rheumatoid arthritis is an autoimmune disease that results in a chronic, systemic inflammatory disorder that may affect many tissues and organs, mainly flexible (synovial) joints. It can be a disabling and painful condition, which can...
People at the centre
THE PROJECT
The project is developed in two parallel areas: work-life balance and outside-work activities. Work-life balance activities aim at improving the relationship between working time and private life, such as Time-saving Services, Flexibility Actions and People Care initiatives....
Chiesi Clinical Trial Data Request Portal
Sharing Clinical Trial Data with Qualified Researchers
Chiesi commits to sharing with qualified scientific and medical Researchers, conducting legitimate research, Patient-level Data, Study-level Data, the Clinical Protocol and the full CSR of Chiesi Farmaceutici S.p.A.-sponsored interventional...
Job opportunities Italy
-
Preliminary Identification Form
If you are a qualified scientific or medical Researcher and you are interested in submitting a Research Proposal to Chiesi Farmaceutici S.p.A. and accessing clinical trial data, please fill in the Preliminary Identification Form.
In order to manage your requests for clinical data, Chiesi...
Clinical Trial Transparency and Data Sharing
Clinical trial transparency and data sharing
Running clinical studies and obtaining results is what clinical development is all about. Sharing results is very important too. Therefore, Chiesi Farmaceutici S.p.A. (Chiesi) is committed to Clinical Trial Transparency and Data Sharing.
As a member of...
Chiesi Clinical Study Register
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse...
Why Chiesi as a partner?
Why Chiesi as a Partner
With a long history of excellence in the pharmaceutical sector, Chiesi combines advanced research and cutting-edge technologies with a deep respect for the environment and local communities. Chiesi's mission is to improve patients' quality of life through innovative...
Chiesi Group Facebook Community Guidelines
Chiesi Farmaceutici S.p.A. (Chiesi Group) Facebook page is designed for sharing information, news and events relating to the world of health or to the Chiesi Group. We are delighted that you are in touch with us on Facebook and hope that we can develop a fruitful and stimulating dialogue...
Where we are
USAChiesi USAOne Boston PlaceSuite 4000Boston, MA 02108
Information on Processing of the Personal Data
SPONTANEOUS REPORTING - INFORMATION NOTICE In accordance with Articles 13 and 14 of the Regulation (EU) 2016/679 of the European Parliament and of the Council on the protection of natural persons with regard to the processing of personal data and on the free movement of such data...
Chiesi's Sustainability
Sustainability at Chiesi
Sustainability has always been a primary concern in the way Chiesi operates, and today represents a crucial element of the strategic vision of the company, which is committed to:
adopting a governance system based on transparency and responsibility;
promoting the...
People at the centre
People at the centre
Chiesi’s values have always been integrated in our business model. Our work and our commitment are driven by the goal of improving people quality of human life, putting people at the centre of our actions, being them our patients or our...
LinkedIn Community Guidelines
Chiesi Group LinkedIn Page – Community Guidelines
The Chiesi Farmaceutici S.p.A. (Chiesi Group) LinkedIn page is designed for sharing information, news and events relating to the world of health or to the Chiesi Group. We are delighted that you are in touch with us on LinkedIn and...
Contacts
Head Office:
26/A, Via Palermo 43122 Parma – Italy Phone +39 0521 2791
Headquarters:
Via Paradigna 131/A
43122 Parma - Italia
Phone +39 0521 2791
Privacy contatti
PRIVACY NOTICE PURSUANT TO ART. 13 OF THE REGULATION (EU) 2016/679
Dear user,
Chiesi Farmaceutici S.p.A. (hereinafter "Chiesi"), the Data Controller pursuant to Article 4 of Regulation (EU) 679/2016 (also known as "GDPR"), wishes to inform you that the personal data provided by you by submitting...
Our approach
Creating Value for the Collective Good
At Chiesi, sustainability is rooted in the principle of creating shared value to benefit all our stakeholders: patients, people, the planet, and communities. It is built into our business strategy as it is central to who we are. Guided by our mission to...
We ACT - Sustainability Manifesto
We live in a time of great changes. The planet is exploited beyond its limits and its equilibriums are in continuous transformation. We are changing ourselves in the way we live and think about our society. The most fragile and vulnerable are paying the price: those who are...
Environment
A healthy planet is the foundation of our human health, giving us the clean air, water, and resources we need to thrive. Yet, climate change, pollution, and biodiversity loss are directly impacting our well-being, leading to increased health risks.
At Chiesi, we are committed to tackling...
Corporate Citizenship
Being a good citizen is a commitment a company makes to taking economic, social, cultural and environmental responsibility for its activities in the communities where it operates. Just like any other citizen, it has rights and duties.
Inspired by the United Nations SDGs, we have created our own...
Communities
At Chiesi, we view corporate citizenship as a fundamental responsibility—one that goes beyond business to encompass economic, social, cultural, and environmental impact in the communities where we operate.
Chiesi ensures that all community activities are carefully considered and that...
Ethics and Transparency
Ethical Conduct
At Chiesi, upholding the highest ethical standards is a daily priority across all aspects of our business. We operate with integrity, fairness, responsibility, transparency, and in compliance with the law, reflecting our mission: "To combine a commitment to results with integrity,...
Medical Information
What is Medical Information?
Medical Information (Med Info) is a core function within Chiesi, and is one of the most outward facing teams responsible for answering hundreds of incoming enquiries from HCPs and consumers about the products we supply and market.
Why is Medical Information...
Chiesi Foundation
Our commitment goes beyond the areas where we operate to improve the health and relieve the suffering of patients with respiratory and neonatal diseases in countries where access to quality healthcare is not always guaranteed. This is the mission pursued by the Chiesi Foundation, a nonprofit...
Benefit Corporation and B Corp
At Chiesi, we believe that the future of our business lies in integrating sustainability into our core strategy. This committment led us to become a Benefit Corporation and pursue B Corp certification to measure our impact.
Certification Notice
Report EFPIA Countries
AUSTRIA
BELGIUM
BULGARIA
DENMARK
FINLAND
FRANCE
GERMANY
GREECE
ITALY
NORWAY
THE NETHERLANDS
POLAND
UK
CZECH REPUBLIC
SLOVAC REPUBLIC
ROMANIA
RUSSIA
SLOVENIA
SPAIN
SWEDEN
SWITZERLAND
HUNGARY
Chiesi People
As a family-owned company, many of our more than 7,000 employees have been with us for 10, 15, 20 years or more, finding alignment with our values and mission. We believe everyone has the right to meaningful work, the freedom to define what that means, and the agency to create a fulfilling career...
European and International Agenda
In accordance with the principles of interdependence deriving from the B Corp movement, we aim to constantly involve stakeholders in our sector (political decisionmakers, patient associations, scientific societies etc.) in order to further develop the regulatory and political framework of the...
Twitter Community Guidelines
Chiesi Group Twitter Profile – Community Guidelines
Chiesi Farmaceutici S.p.A. (Chiesi Group) Twitter profile is designed for sharing information, news and events relating to the world of health or to the Chiesi Group. We are delighted that you are in touch with us on Twitter...
Privacy-SpeakUp&BeHeard
PRIVACY NOTICE
This privacy notice is provided by Chiesi Farmaceutici S.p.A., including its affiliates (together “Chiesi Group“ or “Chiesi”) in compliance with the applicable privacy regulations and is aimed at informing the reporting individuals on how we process...
Patient Organizations Support
Disclosure of the list of Patient Associations supported by Chiesi Farmaceutici S.p.A., in 2022, according to article 4.6 of Farmindustria Code of Conduct.
Association Name
Venue
Contribution Description
Value (€)
European Patients'...
Social Media Guidelines
-
Switzerland
As a member of scienceindustries, Chiesi SA (Chiesi) is commited to publish the data in relation to the interactions with healthcare professionals (HCPs) and healthcare organisations (HCOs) according to the Pharma Cooperation Code (Code). In addition, it is Chiesi ‘s responsibility to publish...
Therapeutics Focus
Therapeutic Focus
As an international biopharmaceutical company, we believe that the best way to meet patient needs is always through valuable collaboration. At Chiesi, our strong expertise in R&D and our global presence drive the development of impactful commercial partnerships. These...
Digital Health
Digital Health
Chiesi’s Digital Health team is tasked with broadening Chiesi’s offerings to patients beyond pharmacological/biological solutions. This enables the company to deliver impact across the patient journey, focusing on improving outcomes through behavioral interventions...
Open Innovation - The Impulse
Brave Innovation for a Brighter Future
The Impulse is Chiesi’s global initiative dedicated to advancing healthcare through bold, patient-centred innovation. We support visionary thinkers and doers who want to transform ideas into impactful solutions.
An impulse fuels our drive. It...
Mentoring the next generation of Nordic startups with NOME
The Impulse, Chiesi’s new innovation initiative is delighted to announce a partnership with NOME, the Nordic Mentor Network for Entrepreneurship. The Impulse and NOME recently entered a partnership whereby Chiesi will be connected with the next generation of Nordic startups in biotech,...
The Impulse shortlists 6 promising startups from Southern and Eastern Europe for pilot projects, through its new partnership with EIT Health
Chiesi’s new innovation initiative The Impulse is delighted to announce the launch of an innovation challenge through an exciting new collaboration with the European Institute of Innovation and Technology, or EIT Health, an EU-funded network of best-in-class health innovators.
The...
Cultivating and accelerating healthcare innovation in Italy
The Impulse by Chiesi and InnovUp, a leading network of Italy’s innovation ecosystem, have joined forces to cultivate and accelerate healthcare innovation in Italy, as well as to engage in advocacy and policy debates on key topics for advancing innovation in healthcare. InnovUp is a...
Taking groundbreaking ideas beyond the lab through R&D with a leading medical university
Earlier this year, The Impulse by Chiesi began a collaboration with Karolinska Institutet, one of the world’s leading medical universities, based in Stockholm, Sweden. Through this collaboration, Chiesi aims to accelerate research and development initiatives for respiratory diseases, rare...
Identifying and supporting promising healthtech startups across Europe
The Impulse by Chiesi is thrilled to announce a dynamic new collaboration with TechTour, a renowned European investor network, to identify and support promising healthtech startups across Europe. This exciting collaboration enables Chiesi to engage with a range of different TechTour programmes, in...
Patients at the Center
Chiesi recognizes each patient as a unique individual and an integral part of the broader community we share. Patient care goes beyond drug development, encompassing the entire healthcare journey. To ensure our solutions meet real needs, we actively collaborate with patient communities, caregivers,...
Global Value Chain
Chiesi follows the United Nations Global Compact definition of supply chain sustainability as "the management of environmental, social and economic impacts and promotion of good governance practices throughout the entire life cycle of goods and services".
This is only possible with the...
Double-digit growth and internal expansion for the Chiesi Group
Chiesi Farmaceutici SpA, a leading international pharmaceutical company focused in the respiratory, neonatology and special care therapeutic areas, closed 2013 with a turnover of more than 1,236 million euro, an increase of 11,8% compared to 2012 (+14% at constant exchange rates).
"All our global...
COPD indication for Foster pMDI
Foster is a fixed combination of beclomethasone dipropionate (corticosteroid) and formoterol fumarate (a long-acting β2-agonist with rapid onset of effect) to be taken by inhalation. In 2006 the drug was approved for the maintenance therapy of asthma; after its first launch in Germany on...
Chiesi tra le prime 10 aziende più ambite dai lavoratori
-
PERSISTENT ASTHMA: THE INNOVATIVE INHALER AVIALABLE IN ITALY
The first extra-fine dry powder inhaler was successfully launched in Italy on October 2013 to address the unmet doctors’ and patients’ need of a user-friendly and safe drug delivery device. Being an high quality alternative to the pressurised metered dose inhaler, this innovative device...
Europe approves Holoclar®, the first stem cell—based medicinal product
Parma/Modena (Italy), February 20, 2015 – The European Commission has granted a conditional marketing authorization, under Regulation (EC) No 726/2004, to Holoclar®, an advanced therapy based on autologous stem cells and capable to restore the eyesight of patients with severe cornea...
80 years of innovation and success in healthcare: Chiesi reports significant international growth in 2015
Chiesi Farmaceutici generated just under €1.5bn in revenue in 2015, a year-on-year increase of almost 10%.
The international footprint of the Group continues to grow: 80% of turnover is now from the non-Italian market.
The expansion of Chiesi’s US affiliate is extremely...
Chiesi is Top Employer again!
Chiesi receives today the Certificate Top Employers Europe for the fourth year in a row. The prize is assigned only to those organisations that create optimal employee conditions, upon evaluation of the HR strategies and policies. The CRF Institute uses a proprietary method based on the HR...
Special Mention to Holoclar at the Italian Galeno Award
Chiesi Farmaceutici has been awarded with the "Special Mention fro innovation" for Holoclar, during the ceremony of the Galeno Award, a prize promoting the most important progresses in the pharmaceutical research. The Galeno Award is considered today the Nobel prize in the...
Alberto, Paolo and Andrea Chiesi winners of the “Entrepreneur of the year 2015” Award
Alberto, Paolo and Andrea Chiesi are the National winners of the EY “ L’Imprenditore dell’Anno 2015” Award. The prestigious recognition, promoted by EY-Ernst & Young and sponsored by Azimut Wealth Management, is now at its 19th edition. The...
Chiesi To Acquire 3 Hospital Products
Chiesi USA, Inc. and Chiesi Farmaceutici S.p.A., Chiesi USA's parent company, announced today that the companies have agreed to acquire worldwide rights of The Medicines Company to Kengreal® (cangrelor) and Cleviprex® (clevidipine), as well as rights to Argatroban for Injection, 50 mg per...
An extrafine ICS/LABA combination decreases COPD exacerbations more than
Parma (Italy), May 17 2016 – In the treatment of chronic obstructive pulmonary disease (COPD) the combination of inhaled corticosteroids (ICS) and long acting bronchodilators LABA (Long Acting Beta2-agonists) reduces moderate and severe exacerbations, and it is recommended for this purpose in...
Patients with COPD benefit from the Chiesi extrafine fixed triple combination ICS/LABA/LAMA: highly effective and easy to use.
Chiesi is the first Company to complete 2 multicenter long-term clinical studies with an extrafine fixed triple combination for COPD
The preliminary results of the two 12-month studies demonstrate that Chiesi extrafine fixed triple combination improves lung function, reduces exacerbations and...
The Lancet publishes the results of Chiesi Farmaceutici TRILOGY study
The Lancet publishes the results of Chiesi Farmaceutici TRILOGY study, which shows one year data on the superior efficacy of the first extrafine fixed ICS/LABA/LAMA triple combination for COPD treatment compared with standard therapy.
The results of the study provide convincing support for the...
Chiesi Farmaceutici is the first company to submit a marketing authorisation application to the European Medicine Agency for a Triple Combination for the treatment of COPD
Parma, September 29, 2016 - Chiesi Farmaceutici SpA (Chiesi) announces today the submission to the European Medicines Agency (EMA) of the marketing authorisation application for the first ICS/LABA/LAMA triple combination. The product is indicated for the treatment of Chronic Obstructive Pulmonary...
The Italian Prime Minister Matteo Renzi, has visited Chiesi Farmaceutici Research Center in Parma
Tuesday, November 8 -- The Italian Prime Minister Matteo Renzi, has today visited Chiesi Farmaceutici at the Research Center in Parma. The Prime Minister scheduled a meeting with Ugo di Francesco, Group CEO, Paolo Chiesi, Vice President, Alessandro Chiesi, Region Europe Director and...
Chiesi Enhances Asthma Portfolio with Acquisition of Atopix Therapeutics
Parma, Italy — November 21, 2016— Chiesi Farmaceutici Spa (“Chiesi”), announced today that it has signed a definitive agreement for the acquisition of Atopix Therapeutics Limited, a UK clinical stage biotechnology company developing novel treatments for asthma. Under...
GOLD 2017 Report: Chiesi Farmaceutici highlights relevant gaps
GOLD 2017 Report: Chiesi Farmaceutici highlights relevant gaps
Chiesi Farmaceutici welcomes the recently published GOLD report but identifies three key elements in the treatment recommendations, which deserve thorough evaluation and further revision:
Limited evidence base...
Chiesi certified Top Employer also for 2017
Chiesi is Top Employer Italy for the ninth consecutive year and Top Employer Europe for the fifth consecutive year, confirming to be among the entrepreneurial excellence for the working conditions of its employees. It is the independent research of the Top Employers Institute to certify it, which...
For the second time, Chiesi’s extrafine fixed dose ICS/LABA/LAMA triple therapy earns a place in the pages of The Lancet, with the publication of Chiesi’s TRINITY study.
For the second time, Chiesi’s extrafine fixed dose ICS/LABA/LAMA triple therapy earns a place in the pages of The Lancet, with the publication of Chiesi’s TRINITY study.
TRINITY is the first study to demonstrate the superiority of triple therapy with a fixed dose combination of an...
Chiesi Group reports an increased turnover in 2016 and consolidates its global presence
Chiesi Group closes 2016 with a turnover of €1.571 million, up 7.0% on 2015 (+9.6% at a constant exchange rate).
The international footprint of the Group continues to grow: 83% of turnover comes from the non-Italian market. Significant growth in the European affiliates, which have now...
Glybera▼ (alipogene tiparvovec) in Europe
Parma, 20 April 2017 - Chiesi Farmaceutici Spa (“Chiesi”) acknowledges that uniQure biopharma B.V (uniQure), have taken the decision to withdraw the ongoing application for the Marketing Authorization Renewal of Glybera, for which Chiesi holds commercialization rights for Europe and...
Trimbow® is the first triple combination in a single inhaler for the treatment of COPD to receive positive opinion from the CHMP in Europe
Chiesi is the first pharmaceutical company to have demonstrated with randomized clinical trials, two of which published in The Lancet 1,2, the efficacy of the triple extrafine combination to prevent exacerbations, improve symptoms and quality of life.
Trimbow is the first fixed triple...
Chiesi Farmaceutici completes the acquisition of European Marketing Rights
Chiesi Farmaceutici completes the acquisition of European Marketing Rights to PROCYSBI® (cysteamine bitartrate) delayed-release capsules and QUINSAIR™ (levofloxacin inhalation solution) in Europe, Middle East and Africa (EMEA) Regions from Horizon Pharma plc
Parma (Italy) – June...
Chiesi Group receives the European Marketing Authorisation for Lamzede®▼(velmanase alfa)
Lamzede® (velmanase alfa) is the first enzyme replacement therapy for the treatment of non-neurological manifestations in patients with mild to moderate alpha‑mannosidosis (AM)
AM is an ultra-rare disorder presenting a broad range of symptoms and its long-term prognosis is generally poor,...
Chiesi Group receives the European Marketing Authorisation for Trimbow® (inhaled corticosteroid / long-acting β2-agonist / long-acting muscarinic antagonist)
Parma, Italy, July 24 2017 Chiesi Group (Chiesi), an international research-focussed healthcare company, today announced that the European Commission has granted the marketing authorisation for Trimbow® for the maintenance treatment in adult patients with moderate to severe chronic obstructive...
TRIBUTE study shows superiority of Chiesi's Trimbow® (Beclometasone dipropionate (BDP), Formoterol fumarate (FF) and Glycopyrronium (GB)) over Ultibro® (indacaterol/glycopyrronium) in reducing COPD exacerbations1
Chiesi completed a long-term clinical study with its extrafine fixed-dose triple combination inhaler (Trimbow®) in a single pressurised metered dose inhaler (pMDI) for COPD patients.
Trimbow met the primary endpoint showing superiority vs Ultibro® in reducing COPD exacerbations.
Full...
Festival Verdi, in anteprima i titoli 2018
-
Jérusalem, le foto di scena inedite
-
Stiffelio, così è nata la prima opera immersiva in Italia
-
Chiesi Farmaceutici per il Festival Verdi
-
La traviata di Busseto, occasione per gli artisti di domani
-
Benvenuti a Windsor, terra di Falstaff
-
Messa da Requiem, guida all'ascolto
-
Messa da Requiem, le immagini esclusive
-
VerdiYoung: il Festival è per tutte le età
-
Gualazzi a tu per tu con Verdi
-
Chiesi enters into an Exclusive ex-US Partnership with Protalix BioTherapeutics for the Development and Commercialization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
Protalix grants Chiesi Ex-US rights to PRX-102, a chemically modified version of the recombinant protein alpha-Galactosidase-A protein
Protalix to receive $25 million upfront payment in consideration for and as reimbursement of the past costs sustained by Protalix, an additional up to $25...
Musica, ovunque e per tutti: Verdi OFF
-
Chiesi Digital Transformation - Digital Safari Workshop with David Orban
Last week Chiesi hosted a digital safari workshop, organized within the company's Digital Transformation program.
The workshop was led by David Orban, investor, entrepreneur, author, blogger, keynote speaker, and thought leader of the global technology landscape. He is also Professor...
Chiesi enters into an Exclusive ex-US Partnership with Protalix BioTherapeutics for the Development and Commercialization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
Protalix grants Chiesi Ex-US rights to PRX-102, a chemically modified version of the recombinant protein alpha-Galactosidase-A protein
Protalix to receive $25 million upfront payment in consideration for and as reimbursement of the past costs sustained by Protalix, an additional up to...
New study published in The Lancet shows Trimbow® (beclometasone/formoterol/glycopyrronium) superiority over Ultibro® Breezhaler® (indacaterol/glycopyrronium) in reducing COPD exacerbations1
The TRIBUTE study showed superiority of Chiesi’s extrafine formulation triple combination, Trimbow® (beclometasone/formoterol/glycopyrronium) over Ultibro® Breezhaler® (indacaterol/glycopyrronium) in terms of rate of moderate-to-severe exacerbations in patients affected by...
Chiesi Group confirmed Top Employer 2018 in Italy and Europe
The award is assigned to 10 affiliates of Chiesi Group. In 2018, the Group celebrates Top Employers for the 10th year running in Italy and for the 6th year running in Europe.
The independent research by Top Employers Institute rewards the Company excellence in HR practices, thanks to the...
Chiesi Group receives positive opinion from CHMP for Lamzede® (velmanase alfa), the first therapy for Alpha-Mannosidosis
Lamzede® (velmanase alfa) is the first pharmacological therapy for the treatment of Alpha- Mannosidosis (AM), an ultra-rare, disabling, genetic disorder1
AM is a lysosomal storage disorder caused by the deficiency in the activity of the enzyme alpha-mannosidase, involved in the cellular...
The Chiesi Group is one of the 8 Italian companies invited by Macron to the French International Summit in Versailles
Versailles (France), January 22, 2018 - The Chiesi Group, represented by the CEO Ugo Di Francesco, took part at the French International Summit. Event wanted by the President of the French Republic Emmanuel Macron, who saw protagonists CEOs and Presidents of the world's largest multinational...
Mario Melazzini, Direttore Generale di AIFA, incontra i giovani ricercatori del Centro Ricerche di Chiesi Farmaceutici
-
Chiesi is the first Italian pharmaceutical Company for investments in Research and Development
The 2017 edition of the EU Industrial R & D Investment Scoreboard of the European Commission places Chiesi Group at the top of the Italian pharmaceutical companies in terms of investments in Research and Development.
Compared to the previous year, the growth of Chiesi Group's investments...
Global Corporate Development : opening of new offices in Boston
Il Global Corporate Development (GCoD)ha recentemente inaugurato nuovi uffici a Boston. Gli uffici si trovano al tredicesimo piano di Post Office Square n° 10, nel cuore del distretto finanziario di Boston. Questa nuova ubicazione permetterà di avere contatto diretto con...
Chiesi hosts groundbreaking ceremony for the Group’s future Headquarters
The pharmaceutical Group’s new head office, which will guide its growth and internationalisation strategies, will be located in Parma and will house around 540 people.
People, innovation, sustainability: three words which sum up the philosophy behind this new project, developed on the...
Chiesi supports The Third Day exhibition, dedicated to the relationship between man and nature
From 20 April to 1 July 2018, the Governor’s Palace, in the heart of Parma’s historic centre, will host a unique exhibition, The Third Day, curated by Didi Bozzini and promoted by the Municipality of Parma. This series of events will provide the city with the opportunity to reflect on...
Chiesi signs a deal with StartUp Health: first investment in the digital area
Chiesi has signed a strategic deal with StartUp Health, a global health innovation company focused on achieving Health Moonshots. StartUp Health has the largest digital health-focused portfolio in the world, consisting of over 235 companies applying technology to solve key challenges such as...
Chiesi and Holostem Announce FDA Orphan Drug Designation for GPLSCD01 for treatment of Limbal Stem Cell Deficiency (LSCD)
Cary, N.C., June 12, 2018 – Chiesi USA (key-A-zee), a specialty pharmaceutical company based in Cary, N.C., and the Italian biotech Holostem Terapie Avanzate S.r.l., announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to an investigational product,...
Protalix BioTherapeutics Expands Partnership with Chiesi Farmaceutici to Include Exclusive U.S. Rights for the Development and Commercialization of PRX-102 (pegunigalsidase alfa)
Protalix grants Chiesi Ex-US rights for PRX-102, a chemically modified version of the recombinant protein alpha-Galactosidase-A protein
The agreement includes an initial investment of 25 million dollars, as a reimbursement for research costs incurred by Protalix, an additional up to $20...
Chiesi Acquires NHCO Nutrition® SAS and strengthens its OTC portfolio in France.
Parma (Italy), September 3 2018 – Chiesi, an international research-focused healthcare Group (Chiesi Group), today announced that it has completed the acquisition of 100% of NHCO Nutrition® SAS (NHCO) shares, a French company specialized in food supplements commercialized in...
Dietro le quinte di un nuovo Festival Verdi
-
Dietro le quinte de Le trouvère
-
Macbeth, le immagini inedite
-
Un giorno a Busseto, Un giorno di regno
-
Attila, le foto esclusive
-
StartUp Health raises 31 million dollars from the Chiesi Group and a prominent group of other large pharmaceuticals companies and healthcare organizations
StartUp Health announced a successful fundraise of 31 million dollars for its Transformer Fund II from a prominent consortium of strategic partners, including, as previously announced in June, the Chiesi Group. Other partners in this fund include large healthcare organizations, multinational large...
COPD, a disease still underestimated by Europeans: absence of perceived risk, according to Eurisko survey.
Only 16% of those interviewed believe they may be at risk, even if the disease is considered serious or very serious in almost all cases (95%).
On average 36% of those who claim to have heard about COPD make reference to the media (radio and TV in particular) as their main source of information....
Chiesi enters in an exclusive global license agreement with TiumBio to develop innovative molecules for respiratory diseases
TiumBio grants Chiesi global rights to develop small molecules targeting transforming growth factor beta (TGF-β) signaling in respiratory indications
This agreement expands Chiesi’s comprehensive R&D program in respiratory diseases with high unmet medical need
Parma...
Chiesi Farmaceutici changes statute to become “Benefit Corporation”.
A Benefit Corporation is a new legal form of business enterprise which represents a paradigm shift and is an expression of a more evolved vision, incorporating a two-fold purpose into its business objective: in addition to the objective of generating profit it also pursues the goal of making a...
Chiesi: “imprese per innovazione” award, Industry 4.0 and Sustainability Special Mentions
Chiesi received the "Imprese per innovazione" award during the Connext event of February 6 and 7. Connext is the first National meeting of industry partnership organized by Confindustria, with the purpose of strengthening collaborations in the production area and in research and innovation...
Chiesi Group receives the EURORDIS Black Pearl Award for innovation in the field of Rare Disease.
Brussels, February 13, 2019 – Chiesi, an international research-focused healthcare Group (Chiesi Group), was awarded yesterday at the EURORDIS Black Pearl ceremony with the Company Award for Innovation. The EURORDIS Black Pearl Award is an annual event held in Brussels to recognise the...
Paolo Chiesi appointed Honorary Doctor at Karolinska Institutet
Paolo Chiesi receives the award for his long-standing commitment to vital treatment of the lungs of premature babies. The ceremony will take place on 10 May in Stockholm City Hall
Stockholm May 10, 2019 – Chiesi Farmaceutici, an international research-focused healthcare Group...
Chiesi Group Enters into License Agreement with Santhera for a treatment for LHON
Chiesi Farmaceutici, an international research focused healthcare group (Chiesi Group) has entered into an exclusive license agreement with Santhera Pharmaceutical, under which Chiesi Group will in-license an orphan drug whose active principle is idebenone for the treatment of Leber hereditary...
Chiesi Group signs an Option Agreement with Inhibrx for Development and Commercialization of INBRX-101 (AAT-Fc)
Chiesi, an international research-focused healthcare Group (Chiesi Group) and Inhibrx, Inc. (“Inhibrx”), a clinical-stage biotechnology company developing a broad pipeline of novel biologic therapeutic candidates, announced today they entered into an agreement granting Chiesi Group an...
Chiesi Group is the largest pharmaceutical group in the world to be awarded B Corp certification
Certified B Corporations meet the highest standards of verified social and environmental performance, transparency and accountability.
Chiesi Group receives the B Corp certification from B Lab, a leading global sustainability non-profit body, in recognition of its corporate sustainability...
Volontariato aziendale in Chiesi Farmaceutici: conclusa la 5° edizione di “Everyone of us is different – Everyone of us is Chiesi”
-
Chiesi Group confirms positive trend to date for 2019
The latest available statistics reveal that, during the first six months of the year, overall revenues increased by 11.6% vs the first 6 months of 2018
These results confirm 2019 to be a year characterised by significant growth for the Group which has recently celebrated a key strategic...
Chiesi Group Announces Closing of Licensing Transaction with Santhera for an orphan drug in LHON
Chiesi Farmaceutici, an international research-focused healthcare group (Chiesi Group), announces the closing of the licensing transaction with Santhera Pharmaceuticals. As per the agreement, Chiesi Group is in-licensing a product whose active principle is idebenone for the treatment of...
We ACT Day 2019: Chiesi sets itself the challenge of becoming carbon neutral by 2035
Today all of the Group’s affiliates, employees, communities and company partners commit to building a sustainable future
Parma, September 25th 2019 – Chiesi Farmaceutici, an international group focussed on improving the quality of people’s lives (the Chiesi Group),...
SINGLE-INHALER EXTRAFINE TRIPLE THERAPY OF INHALED CORTICOSTEROID PLUS LONG-ACTING Β2-AGONIST PLUS LONG-ACTING MUSCARINIC ANTAGONIST THERAPY IMPROVES LUNG FUNCTION AND REDUCES ASTHMA EXACERBATIONS1
Data from two randomised, double-blind, parallel-group, active-controlled studies on the efficacy and safety of single-inhaler triple therapy in adult patients with uncontrolled asthma is published in The Lancet for the first time
TRIMARAN and TRIGGER compared the single-inhaler triple therapy...
VERDI OFF 2019: La musica invade la città!
-
VERDIYOUNG: IL FESTIVAL È PER TUTTE LE ETÀ
-
10 OTTOBRE: Buon compleanno Maestro!
-
AL REGIO NUOVE #PROSPETTIVE CON IL BAREZZI FESTIVAL
-
Chiesi Group receives Diversity Leaders Award 2020
The Group is now one of the top 70 companies worldwide out of a total of 700.
Out of the 300 Italian companies involved, Chiesi ranks 1st among the 8 companies qualifying for the ranking.
Parma, November 20th 2019 – Chiesi Farmaceutici, a research-focused international...
DA 0 A 99 ANNI. CON REGIOYOUNG IL TEATRO È PER OGNI ETÀ!
-
Chiesi outlines €350 million investment and announces first carbon minimal pressurised Metered Dose Inhaler (pMDI) for Asthma and COPD
Market leader in respiratory innovation highlights potentially harmful1 consequences of short-term thinking in rush to introduce policies to switch patients to so-called ‘green inhalers’ as they announce breakthrough environmentally friendly pressurised metered dose inhaler (pMDI)...
VERDI 2020: annunciati i titoli del Festival
-
XIX Festival Verdi: un’edizione da record!
-
Quattro titoli del ’900 per la Stagione Lirica 2020
-
Chiesi Group joins the Cooperative Compliance Programme run by the Italian Revenue Agency
Parma, December 18th, 2019 – Chiesi Farmaceutici, an international research-focussed group (the Chiesi Group), announces it has been admitted to the Cooperative Compliance Programme set up by the Italian Revenue Agency (as provided by Legislative Decree 128/2015). Notification of its...
La Stagione Concertistica, realizzata con il sostegno di Chiesi
-
Chiesi Group sponsors Parma Capital of Culture 2020
Parma, 10th January 2020 – Chiesi Farmaceutici, an international research-focussed pharmaceutical group (the Chiesi Group), announces it is set to take part in Parma Capital of Culture 2020.
Key elements of Parma 2020 are promoting public-private partnerships and opening a dialogue...
Chiesi Group and Apotex Inc. finalize agreement for acquisition of Ferriprox® (deferiprone)
Chiesi Group expands distribution network via acquisition for worldwide product rights.
Chiesi Group will establish offices in Toronto, Canada.
PARMA, Italy, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Chiesi Farmaceutici S.p.A., an international research-focused healthcare...
Chiesi Group confirmed Top Employer 2020 in Italy and Europe
Parma, January 30th 2020 – Chiesi Farmaceutici, an international research-focussed pharmaceutical group (Chiesi Group), has once again qualified for the title of Top Employer 2020 in Italy and Europe.
Ten of the Group’s affiliates obtained the certification this year: Italy was...
Chiesi Group Announces Establishment of New Global Rare Diseases Division
Specialized division focused on research and product development for rare and ultra-rare diseases highlights Chiesi’s commitment to building a brighter future for patients
Chiesi Global Rare Diseases unit will harness the full resources of Chiesi Group to support rare disease communities,...
Al Regio tutte le anime della danza
-
Chiesi Group increases support measures and announces new funds for employees, patients and healthcare providers in response to COVID-19 pandemic
Chiesi Group increases support measures and announces new funds for employees, patients and healthcare providers in response to COVID-19 pandemic
The Group commits €3 million for donations to support the ongoing emergency in Italy
Sustained efforts designed to ensure continuity of...
Chiesi Farmaceutici e GSK Parma: al via i test sierologici gratuiti per i dipendenti
-
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Submission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease
CARMIEL, Israel, May 28, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based...
Happiness&Wellbeing: Maria Paola Chiesi at the Vatican workshop
The Covid-19 pandemic has been certainly an opportunity to reflect on the lifestyle of our society and on the future of the new generations. Alongside the health crisis, however, on the path to our “normal” life, the risk is to forget other equally important crises, such as the social...
Chiesi Group and Holostem Terapie Avanzate announce transfer of Holoclar® from the Chiesi Group to Holostem
Parma and Modena, 16 June 2020 – Chiesi Farmaceutici, international research-focussed group (Chiesi Group), and Holostem Terapie Avanzate, top Italian biotech company entirely dedicated to the development, production, registration and distribution of medicinal products for advanced therapies,...
Bioasis and Chiesi Group Announce Rare Diseases Strategic Alliance
Deal provides Chiesi Group with worldwide, exclusive license to use Bioasis xB3 TM platform for delivery of undisclosed enzymes in treatment of four lysosomal storage disorders.
Under terms of the agreement, Bioasis will receive an upfront payment of US$3 million, additional potential...
Thomas Eichholtz appointed new Head of Global Research and Development at the Chiesi Group
Parma, July 2, 2020 – Thomas Eichholtz is the new Head of Global Research and Development at the Chiesi Group. A senior leader with over 25 years’ experience in Research and Development across the entire value chain, from target identification to registration and post-marketing...
Bioasis and Chiesi Group to Host Webcast on July 16, 2020
GUILFORD, CONN., U.S.A. and PARMA, ITALY – BIOASIS TECHNOLOGIES INC. (“Bioasis”) (TSXV:BTI.V;
OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TMplatform technology for the delivery of therapeutics across the blood-brain...
The B Change: the Instant Book by Pharmastar is online
The Instant Book "Doing business today is also an environmental and social value. The B Change" is online. It has been edited by the editorial staff of Pharmastar and it is dedicated to the international movement of the B Corps. This document is intended to provide a detailed overview of the B Corp...
Chiesi publishes its annual report: Group generates almost €2 billion and obtains B Corp certification in 2019
€1,992.81 million, around 6,000 employees, an 11% reduction in CO2 emissions and more than a fourfold increase in renewable energy consumption – these are some of the Group’s figures;
The report, which is based on the approach of renowned US economist and essayist Jeffrey Sachs,...
CHIESI JOINS THE MOVEMENT OF ITALIAN B CORP COMPANIES “UNLOCK THE CHANGE”
The Chiesi Group is pleased to take part in the “Unlock The Change” campaign, the awareness-raising project launched by the B Corp community, together with Nativa, one of the leading companies of the movement in Italy. The initiative has been launched last Thursday, July...
Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH).
CAMBRIDGE, Mass. and Parma, Italy – September 16, 2020 – Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients and Chiesi Farmaceutici S.p.A., an international...
Chiesi Farmaceutici President appointed Knight of the Légion d’Honneur
Parma, 18th September 2020 – Chiesi Farmaceutici, an international research-focussed group, announces the appointment of Dr. Alberto Chiesi, President of the Group, to Knight of the Légion d’Honneur, the highest order of merit awarded by the Republic of France.
The appointment,...
We ACT Day 2020: the third edition of Chiesi’s event for a sustainable future
This year, all of the Group’s affiliates, employees, communities and the company’s partners will be attending a virtual edition of the event to confirm Chiesi’s commitment towards people, the community and the environment.
Parma, 24th September 2020 – Chiesi...
Il Gruppo Chiesi accoglie la visita ufficiale del Sottosegretario di Stato Stanislao Di Piazza
-
Italy for Climate: Chiesi at the forefront for the future of Italy
Making the climate the pivot of the strategy for economic and employment recovery: this is the objective of Italy for Climate, the initiative promoted by the Fondazione per lo Sviluppo Sostenibile and a virtuous group of companies (Conou, Davines, e2i, ERG, illy, ING), including Chiesi Group, with...
Regeneration 20|3, the first global meeting to launch the program is in Parma on October 15 and 16.
The 20|30 temporal frontier is essential: we have no more than 10 years to give a concrete response to the problem of the climate change, while working on a new regenerative model that puts social equality, happiness and well-being of individuals at the center of the strategy, as well as economic...
Maria Paola Chiesi received by the President of the Italian Republic for the 2020 Bellisario Award ceremony
Chiesi Farmaceutici receives the award reserved to large Companies and recognises their outstanding contribution to gender equality and to enhancing the value of women in the workplace
Parma, October 15th, 2020 – Chiesi Farmaceutici, an international research-focussed pharmaceutical...
Chiesi USA, Inc. announces FDA approval of Bronchitol® (mannitol) inhalation powder
Bronchitol® indicated as add-on maintenance therapy to improve pulmonary function in adult patients with cystic fibrosis (CF)
CARY, NORTH CAROLINA, NOVEMBER 02, 2020 – Chiesi USA, Inc., the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused...
World Prematurity Day: Chiesi is at the forefront for preterm babies
November 17th it’s the World Prematurity Day (WPD). The WPD aims at raising awareness of the challenges of preterm birth globally, one of the largest cause of perinatal and neonatal mortality and morbidity in children (source: World Health Organization). Without an appropriate treatment,...
Chiesi Group receives Diversity Leaders Award 2021
The Group achieves the 10th position (just one other Italian company is between the first 10), among the most inclusive companies in Europe and the 1st position in the Pharmaceutical and Biotechnology sector;
In Italy, Chiesi ranks 2nd among the 35 companies qualifying for the...
Chiesi launches “The Art of Caring”, a journey in search of the link between Parma, officinal treatments and pharmaceutics
Parma, November 17, 2020 – Chiesi Farmaceutici, an international research-focussed pharmaceutical group, announces the launch of the website www.artedellacura.com. A cultural and historical account consisting of three virtual itineraries which set out to discover some of the places...
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Extension of PDUFA Date for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease
CARMIEL, Israel, November 27, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based...
Kaia Health and Chiesi Group Announce Strategic Partnership to Commercialise Kaia COPD Pulmonary Rehabilitation App in European Markets
Agreement marks a historic partnership for respiratory care in Europe
MUNICH and PARMA, November 30, 2020 - Kaia Health, a leading digital therapeutics company, and Chiesi Group, an international research-focused healthcare group, announced that they have entered into an exclusive...
“Infermieri, a viso aperto”, a photographic project bringing to light the faces and stories of those who help patients every day
At infermieriavisoaperto.it shots taken by photographer Settimio Benedusi visually tell the story of nursing professionals who are fundamental to our healthcare service.
This virtual photographic exhibition was promoted and set up by the Chiesi Group under the patronage of the FNOPI, the...
Il Gruppo Chiesi firma accordo integrativo all’avanguardia sui diritti dei lavoratori
-
Sinfonia n.9 di Ludwig van Beethoven
-
Chiesi Headquarters: an innovative, sustainable and people-friendly “home”, the first building in its category to be certified “LEED Platinum” in Italy. A people-oriented project.
The Group’s head office in Parma: a new facility housing more than 540 employees.
People, Innovation, Sustainability form the foundations on which the headquarters were built. Designed on the basis of a new vision of the workplace as a shared space, centred on respect for environment and...
Chiesi Group receives the European marketing authorisation for Trimbow® (beclometasone dipropionate, formoterol fumarate, glycopyrronium) an extrafine formulation fixed triple combination therapy for the treatment of asthma
Trimbow is the first extrafine formulation fixed triple combination therapy in a single inhaler to be approved for use in appropriate asthma patients.1,2 This follows the 2017 approval of this therapeutic option for the treatment of appropriate moderate to severe chronic obstructive pulmonary...
Chiesi Global Rare Diseases Recognizes Rare Disease Day Highlighting Importance of Staying Connected for Information and Support
Company sponsors #wewearstripes social media campaign calling on participants to share photos to express support for people affected by rare diseases
Company to light up offices around the world including Italy, the United States, and Canada
Parma (Italy) - February...
Chiesi Group: performance is up in 2020
The Chiesi Group currently employs 6,389 people worldwide, 2,119 of whom are in Italy and has a turnover of € 2 billion 229 million.
Chiesi’s business comprises 30 affiliates, 7 research centres, 3 production sites and a commercial presence in a total of 90 countries.
These results...
The Chiesi Group is on Twitter!
After the launch of Facebook in 2020 and the continuous growth of the Group’s activities on LinkedIn, Chiesi Group has decided to take a further step in the Social Media world to communicate more directly with its stakeholders.
On Twitter (as on Facebook and LinkedIn)...
Chiesi continues cultural transformation with new visual identity that mirrors patients’ language and experiences
New visual identity is the first public manifestation of Chiesi Group’s continued transformation as a B Corp certified business
Patients’ experiences and perception of Chiesi at the heart of the new corporate identity
Parma (Italy), March 22, 2021 – Chiesi, the...
New record for the Chiesi Group, which is confirmed top Italian pharmaceutical company for number of patents filed
The Chiesi Group is the number one Italian pharmaceutical company and ranks fourth among Italian companies across all sectors for filing the highest number of patents. The details were published by the European Patent Office (EPO) when the 2020 official data relating to the number of patent...
Covid-19: continua l’impegno del Gruppo Chiesi per la sicurezza dei suoi dipendenti e della comunità
-
D&I Policy: a further demonstration of Chiesi's commitment
At Chiesi Diversity & Inclusion (D&I) is part of our culture: as a Benefit company and a certified B Corp, we aim to further enhance an inclusive and open approach in our daily actions, ensuring the well-being of our people, openness to others, a sense of welcome and thus improving...
Chiesi Group receives European Marketing Authorisation for its triple combination therapy inhalation powder (beclometasone dipropionate, formoterol fumarate dihydrate and glycopyrronium) in extrafine fixed formulation delivered through NEXThaler, for the treatment of moderate to severe COPD
Chronic obstructive pulmonary disease (COPD) patients for whom a dry powder inhaler device is preferred, can now benefit from an extrafine formulation fixed triple combination therapy containing an inhaled corticosteroid (ICS) / long-acting β2-agonist (LABA) / long-acting muscarinic...
Macbeth presentato al XX Festival Verdi vince il XXXX Premio Franco Abbiati della Critica Musicale Italiana
-
Chiesi Group is among "Sustainability Leaders 2021" companies in Italy
Chiesi Group, the largest international pharmaceutical Group certified B Corp, is among the top 150 Italian companies to be awarded "Leaders in Sustainability 2021".
The recognition comes from the survey conducted on approximately 1200 Italian-based corporations by Statista, a leading...
New organisational order for the Chiesi Foundation
Maria Paola Chiesi, former Coordinator of the Foundation since 2010, succeeds Dr Paolo Chiesi. She is supported by Massimo Salvadori, Coordinator of the Chiesi Foundation since February.
Parma, May 3 2021 – On May 1 Maria Paola Chiesi was appointed President of the Chiesi...
Chiesi Group calls for #ActionOverWords in the fight against climate change
Chiesi Group, the largest international pharmaceutical company certified B Corp, reinforces 2035 carbon neutral target with #ActionOverWords campaign to encourage measurable sustainability commitments and invite accountability.
Parma (Italy), 10 May, 2021 – Chiesi Group, the...
Chiesi accelerates path toward full sustainability despite Covid-19 pandemic
Ensuring continuing medical treatment for patients has been top priority during Covid-19 pandemic.
Focus on Diversity & Inclusion in the workplace: 53% of all employees are women – ratio of female workers even higher in R&D (64%).
All the company’s 2020 activities, data and...
ERS Congress 2021 – Important updates on Asthma and COPD treatments presented at the Symposium organised by Chiesi “Unlock Every Breath: finding the right key to improve Respiratory Therapy”
Chiesi Group supports the European Respiratory Society Congress with the organization of a Symposium dedicated to the latest findings on advanced treatments of Asthma and COPD.
On Tuesday 7th September, a panel of high-profile and internationally recognized speakers will discuss during...
We’re all aware of the climate crisis, but we’re not talking about its impact on respiratory health.
By Ugo Di Francesco, CEO
After a summer of wildfires and flooding in Europe and further afield, we’re increasingly aware of the devastating impacts of climate change. Yet whilst the immediate effects of higher temperatures and extreme weather events are becoming clear, we are not...
CLIMATE CHANGE – A MAJOR THREAT TO RESPIRATORY HEALTH IN EUROPE SAYS NEW REPORT FROM ECONOMIST INTELLIGENCE UNIT
Panel of experts calls for urgent policy action
Climate change and its impact on lung health: a focus on Europe says climate change is damaging respiratory health in many ways not commonly known[1]
In Europe, climate change is particularly affecting the vulnerable in society, but...
Chiesi receives positive ESG rating from independent rating agency Cerved
Chiesi Group has received an ESG rating A with an overall ESG score of 73.7 out of 100
Cerved Rating Agency: “Chiesi is among the best performing companies in the Healthcare Products sector”
Chiesi particularly stands out for environmentally friendly product innovation and employee...
We ACT Day 2021: this year’s edition of Chiesi’s event for a sustainable future
People, patients, communities, and environment: these are the four cornerstones of the 2021 edition and the strategy of the Chiesi Group, whose commitment has always been to act as a force for good, promoting a mindful and alternative way of doing business
Parma (Italy), September 23,...
Chiesi Research Centre: 10 years’ scientific innovation serving the community
The Group’s R&D hub in Parma employs 638 people, 498 of whom are researchers, and currently has a total of 45 R&D projects underway;
In 2020, Chiesi invested €448 million in R&D activities, representing more than 20% of its turnover;
The building, which was officially...
Chiesi supports the São Paulo Declaration on Planetary Health
Chiesi is proud to have joined the São Paulo Declaration on Planetary Health, an unprecedented, urgent call to adopt a new holistic approach to the health and well-being of the people and the planet.
The Declaration, authored by the Planetary Health Alliance, a global consortium...
The President Alberto Chiesi guest at the Farmindustria roadshow
The Parma step of the Farmindustria roadshow “Innovation and Value Production - The pharmaceutical industry: a heritage that Italy cannot miss” was held yesterday at the GSK plant in San Polo di Torrile.
Our President Alberto Chiesi, speaking on behalf of the Group, underlined the...
Head of Chiesi Global Rare Diseases Recognized at RARE Champions of Hope Awards 2021
Chiesi Global Rare Diseases was launched with a central mission in mind: “Revolutionize the lives of people living with rare diseases.” The patient voice shapes our team. That is why it is so important to join together and celebrate the strength of the rare disease...
Chiesi wins the Diversity Leaders Award for the third consecutive year
Chiesi is once again one of the best European companies in terms of Diversity and Inclusion: for the third year running, the Group received the 2022 Diversity Leaders Award, as one of the top 50 European companies (36° position) out of a sample of 850 companies listed. The Group ranked 2°...
“Helping the World to Breathe” - Chiesi Group among the protagonist of the ATS docuseries
Chiesi’s commitment to creating a shared value for patients, society, and the environment is at the center of “Helping the World to Breathe” an inspiring docuseries promoted by the American Thoracic Society (ATS), global leader in in respiratory health. The aim of the series is to...
Partners and suppliers protagonists of Chiesi Vendor Day 2021
Chiesi Vendor Day 2021, the event dedicated to the Group's suppliers at an international level, was held on 17th November.
Chiesi's suppliers represent a true value network, which is essential for the Company and for its approach to sustainability: in order to ensure that its sustainable...
Chiesi and UCB enter global license agreement for zampilimab a novel monoclonal antibody for fibrotic lung diseases
UCB has granted to Chiesi global exclusive rights to develop, manufacture, and commercialise zampilimab, a monoclonal antibody targeting transglutaminase 2 (TG2), an enzyme associated in fibrotic diseases;
Zampilimab complements Chiesi’s existing respiratory pipeline by adding a potential...
World Prematurity Day: Chiesi’s commitment for the premature babies
At Chiesi we are committed to saving the life of the premature babies and to improving the quality of their life and the air they breathe. For this reason, this year to celebrate the World Prematurity Day (November 17), we launched several initiatives to engage our people all around the...
Il Gruppo Chiesi presenta “Parma 2030: La città sostenibile”
-
Chiesi Group Headquarters takes centre stage in the monograph “SPAZIO LAVORO ARCHITETTURA” (SPACE WORK ARCHITECTURE) Electaarchitettura editions
The volume follows the project of the new, innovative, and sustainable headquarters of the Group, opened in Parma in June 2020 based on a project by EFA architectural studio
Parma (Italy), December 13, 2021 – The Chiesi Headquarters in Parma, the international research-focused...
Chiesi Group focuses on biological drugs: an investment of 85 million euros for an international centre of excellence in Parma
The Biotech Center of Excellence Plant will be operational from 2024
The presentation event in Rome with the Italian Minister of Economic Development, Giancarlo Giorgetti
Chiesi Group is entering into a constantly growing sector, confirming a corporate culture focused on the patient, at every...
A new clinical framework redefines the diagnosis of COPD Exacerbations
The recommendations of an international expert panel to update the definition and severity classification of chronic obstructive pulmonary disease (COPD) exacerbations will be presented by Professor Bartolome R. Celli at the 2021 International Meeting on Asthma and COPD in Florence
Physicians...
Why biotech world needs new plants
The development of biological products has been continuously and steadily increasing in the last decade: in the global market, according to the data of the Biologics Global Market Report 2021, in the last 30 years the sector has grown at an annual rate of more than 12%. Moreover, the volume of...
Chiesi France receives Choose France’s “Contribution au plan de relance (Contribution to Stimulus Plan)” special award from the Minister for Territorial Cohesion and Relations with Local Authorities
Blois (France), January 17, 2022 - On Monday 17 January, Chiesi had the honour of welcoming the Minister for Territorial Cohesion and Relations with Local Authorities, Ms Jacqueline Gourault, at its industrial site in La Chaussée Saint-Victor.
Following the postponement of the Choose France...
The way towards a sustainable and resilient healthcare
The collaboration among governments and the pharmaceutical industry has the power to deliver outcomes to patients at first, but also to society and economy. Therefore, pharma companies should be considered as a catalyst towards a sustainable and resilient healthcare system, following...
Solidarity actions to support the people affected by the war
Like many around the world, the people at Chiesi are shocked by the ongoing conflict as we witness the distress of all those affected. Chiesi strongly condemns all acts of violence, and we call for a peaceful and immediate resolution of the ongoing conflict in Ukraine.
In more than 85 years of our...
Koura opens world’s first HFA 152a medical propellant production facility
New HFA 152a production facility will produce low global warming potential (GWP) propellants for pressurised metered dose inhalers (pMDIs).
The new propellant will reduce the carbon footprint of pMDI inhalers by up to 90%, down to a similar level as a dry powder inhaler (DPI).[1]
New inhaler...
Chiesi Group continues to grow
Chiesi Group turnover of €2.42bn supported by strong international growth of 8.6%
Growth across global markets; China up 22%, US up >10%
Continued focus on innovation: Chiesi invests almost 20% of turnover in R&D in 2021
Chiesi recognised as Top Employer in eight global...
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Topline Results from the 24-Month Phase III BALANCE Clinical Trial of PRX-102 for the Treatment of Fabry Disease
PRX-102 successfully met the primary endpoint on kidney function in active control, non-inferiority study vs. agalsidase beta.
Topline results demonstrated a favorable tolerability and immunogenicity profile for PRX-102.
BLA resubmission planned for the second half of 2022.
CARMIEL, Israel...
Chiesi acquires pioneering therapeutic monoclonal antibodies portfolio against EMAP II as potential treatment for PAH
New investment will progress potential treatment of pulmonary arterial hypertension (PAH), a rare condition which causes high blood pressure and remodeling in the blood vessels that supply the lungs and can lead to heart failure.
Current approved medications mainly address the symptoms of this...
A musical manifesto to rewrite the future
The third edition of “Respira con il Cuore”' reflects on the complexity of today for young people and the hopes of tomorrow
Music has the power to inspire change, shape the collective culture of an entire generations and enhance the sense of well-being. It is also known to have...
Innovating for the health of the planet and people, starting from the little things
Designing a carbon minimal inhaler is a complex challenge: Maria Paola Chiesi talks about one of the most ambitious projects of the Group to reduce its carbon footprint
Frequently, when talking about the environment, we use the metaphor of “planet’s health”, but we seldom...
Dear colleagues, it's showtime!
Corporate theater to learn about oneself and recognise each other
More and more often one hears of team building, which, in the field of human resources, is the set of training activities put in place by the company to enable its employees to develop a set of soft skills useful for...
The Art of Healing
How to put patients at the center and provide holistic support
by Maria Paola Chiesi, Shared Value & Sustainability Head of Chiesi Group
A trip to the emergency room is never a pleasant experience. Being a parent rushing to the ER with a young child, who may not understand the concepts of...
CO2alizione Italia: not just a declaration of intent
More than sixty Italian companies have formalised their commitment and made an alliance for climate neutrality
Atmospheric concentrations of CO2 and other major greenhouse gases represent the greatest threat to the health of the planet and the species living on it. To keep faith with the...
New record for Chiesi Group: in 2021 it’s confirmed top Italian pharmaceutical company for number of patents filed
According to the official data published by the European Patent Office (EPO), also for 2021 Chiesi Group has been confirmed as the first Italian pharmaceutical company and ranks fourth among Italian companies across all sectors for filing the highest number of patents.
An important...
Chiesi Group joins Biden Administration pledge to decarbonize healthcare sector
Chiesi joined the Biden Administration for a White House event on June 30, with the U.S. Department of Health and Human Services (HHS), where Maria Paola Chiesi, Shared Value & Sustainability Head of Chiesi Group, and industry colleagues pledged meaningful action to decarbonize the healthcare...
Chiesi tracks actions taken for a healthier, more sustainable future
Chiesi’s Annual and Sustainability Report 2021 is released today;
Progress towards business, environmental and social targets is strong;
Company is joining forces with all stakeholders to advance sustainable healthcare.
Parma (Italy) July 14th, 2022 – Chiesi, the...
First carbon minimal pMDI is on track with the goal to benefit patients and planet
Chiesi Group announces positive results of pharmacokinetic (PK) studies completed in May 2022 on a leading inhaler in development for the treatment of asthma and COPD, formulated with a new low global warming potential propellant.
Promising results with the new formulation show a similar...
A new EU proposal to protect people and planet by reducing F-gases
The health of people and the environment are closely interconnected. In fact, many conditions, including heart and respiratory diseases, are linked to air pollution[1], which in many cities goes far beyond the set limits. This has serious implications, including an increase in hospitalisations,...
Chiesi announces the departure of Ugo Di Francesco as CEO of the Group
The Board of Directors and the Management Team will ensure leadership continuity in this transitional phase until a new CEO is formally appointed.
A new chapter opens at Chiesi as the 11-year tenure of CEO Ugo Di Francesco comes to a close at the end of 2022. The...
Chiesi Group brings together experts to discuss care for respiratory patients and presents a new treatment option for COPD at ERS Congress
Chronic obstructive pulmonary disease, or COPD, is the third leading cause of death in the world, causing 300,000 annual deaths in Europe1
At the European Respiratory Society Congress, Chiesi Group presents an additional option to address the needs of COPD patients: Chiesi’s extrafine...
Giacomo Chiesi awarded by PharmaVoice100
Since 2005, PharmaVoice100 has been celebrating men and women who have distinguished themselves in the life sciences for their innovative approaches, becoming a benchmark for their peers, companies, and the entire sector.
For the 2022 edition, PharmaVoice also named Giacomo Chiesi, Head of Global...
Chiesi is recertified as a B Corp and sets new tougher objectives for action by 2025
The Group has increased its B-Impact score by 16.3 points, with 103.8 out of 200 compared to its first certification in 2019;
The recertification process by B Lab identifies further focus for action and continuous improvement.
Parma (Italy) September 22nd, 2022 – The B Corp...
Fostering innovation for rare diseases in Europe: Chiesi supports the RDR Challenges Call
Although individually infrequent, the more than 10,000 rare diseases represent a major issue in health care. While they affect up to 30 million people in Europe, research in the field of rare diseases is hampered by the specificities of complex clinical phenotypes or the scarcity of data. Tackling...
Chiesi recognized by Biden Administration for its support and commitment to greater resilience in the fight against climate change
Decarbonize the healthcare sector and make healthcare facilities more resilient to the effects of climate change. It is the goal that Biden Administration’s wants to achieve reducing emissions by 50% by 2030 and achieving net zero emissions by 2050.
A goal perfectly in line with...
Chiesi Group and Aptar partner to bring to market Disease Management Platform for Patients with Asthma and COPD
The new Digital Health Solution aims at offering patients and healthcare professionals a comprehensive set of services and solutions targeted at improving outcomes for chronic respiratory diseases.
Parma (Italy) and Crystal Lake (Illinois) October 18th, 2022 – Chiesi Group, the...
“Vendor Day”: the role of Chiesi Group’s Value Chain in shaping the future
by Guido D’Agostino, Head of Global Procurement of the Chiesi Group
Vendor Day, an event staged annually since 2019, is a unique opportunity to meet our partners and suppliers in order to present, discuss and share the strategic projects launched by Chiesi during the year. But, above...
Chiesi Foundation e l’Ospedale di Parma celebrano la Giornata Mondiale della Prematurità
-
Energize Programme: a shared commitment to accelerate the adoption of renewable energy in the pharmaceutical sector
The Chiesi Group, which has always been active in the challenge against climate change, supports the Energize Programme which aims to accelerate the adoption of renewable energy within the pharmaceutical value chain.
Energize, the result of a collaborative effort between companies in the industry...
Chiesi Group’s new Biotech Center of Excellence brings the future of medicine to Parma
The new center of excellence for the development and production of biologic drugs, currently under construction, will be built in Parma in the area of the production plant;
Construction of the building is rapidly progressing, and it is scheduled to receive its first technological installations...
Chiesi Group endorses the Manifesto Against Gender-Based Violence
The Manifesto was signed with the CGIL, CISL, and UIL trade unions on the International Day for the Elimination of Violence Against Women.
The goal is to ensure that all Group employees adopt respectful and considerate behaviour.
Parma (Italy) November 28, 2022 – On the...
Chiesi Group communicates that it is not involved in the events concerning the Holostem company
Parma (Italy), December 5, 2022 - Following the recent statements appeared in the media, Chiesi Farmaceutici would like to reiterate that the Company is not involved in the events concerning the company Holostem Terapie Avanzate s.r.l. ("Holostem"). The investments in support of Holostem have been...
“Play the Rare Game for the Rare Ones”: parte da Parma la prima catena di passaggi virtuali di palla ovale per sensibilizzare sulle malattie rare
-
From cells to packaging
The Biotech Center of Excellence brings the future of medicine and science to Parma
With the ground-breaking ceremony on November 21, 2022, construction work for the new Biotech Center of Excellence is progressing apace and according to plan. The new hub for the development of biological...
Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc
- Transaction expands Chiesi’s rare disease medicine portfolio
- All cash acquisition at US$14.50 per ADS, plus Contingent Value Rights of up to an additional US$2.50 per ADS based on certain Filsuvez® milestones being achieved
- Total Transaction value of up to US$1.48...
Chiesi’s new interim CEO
Chiesi Group General Counsel, Marco Vecchia, steps in as Interim CEO
Parma (Italy) December 16th, 2022 – After Chiesi Group Chief Executive Officer (CEO) Ugo Di Francesco left the company on 15 December, the Board of Directors appointed Marco Vecchia as Interim CEO on 16 December....
Important recognitions for Chiesi Group from the Carbon Disclosure Project (CDP) and Cerved Rating Agency
Chiesi Group has been named on Carbon Disclosure Project’s Climate Change A List for its commitment to climate action and transparency.
The Group has also received from Cerved Rating Agency the AA ESG rating with an overall score of 75.1 out of 100.
According to the independent rating...
Discovering ESG Criterias (Environmental, Social and Governance), the Chiesi Group's committment
ESG, short for Environmental, Social and Governance (ESG), is a widely used term these days, and ESG performance – along with commercial results – has become a key metric in annual reports. No longer is success measured by financial numbers alone. It’s about making a difference -...
Chiesi appoints Giuseppe Accogli as new Group CEO
Giuseppe Accogli is a successful Executive Leader with 25 years of international experience in the Med-tech sector of reputed and complex companies such as Tyco Healthcare (Covidien), Baxter and Medtronic.
“As CEO, I strive to enable our leaders, people and partners to achieve even greater...
The Alphabet of Sustainability
A game of chess where the players are the institutions, the governments, and the companies, and we, as individuals, are the pawns. A global game in which the chessboard is our planet.
With this metaphor, Francesco Morace defines sustainability and opens his book “L’Alfabeto della...
The Chiesi Group and gender equality: a concrete achievement now certified by Bureau Veritas
Inclusion, gender equality and integration should be three pillars of our society, essential foundations of a more prosperous and sustainable world. Although this has been discussed for a long time – in Italy, the first steps were taken in 1919 with Law no. 1176 – there is still a long...
Chiesi Group stands in solidarity with the people of #Turkiye and #Syria
Chiesi Group stands in solidarity with the people of Turkiye and Syria and our wholehearted sympathy goes to those affected by the earthquake that has dramatically hit these regions.
We are in ongoing dialogue with international humanitarian organisations that are...
Chiesi Global Rare Diseases Announces FDA Approval of Lamzede® (velmanase alfa-tycv) for Alpha-Mannosidosis
First and only enzyme replacement therapy for the treatment of non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients;
Ultra-rare progressive disease presents with wide range of symptoms.
BOSTON, February 20, 2023 – Chiesi Global Rare...
Chiesi Global Rare Diseases Presents Long-Term Results from Phase 3 BALANCE and BRIGHT Studies in Fabry Disease at the 19th Annual WORLDSymposium™ Research Meeting
Company also presents insights from the SPARKLE registry in alpha-mannosidosis that highlight a delay in diagnosis, identify the most frequent genetic MAN2B1 variant in enrolled participants, and report on real-world clinical profiles.
BOSTON, February 24, 2023 – Chiesi Global...
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease
- European Commission decision anticipated in beginning of May 2023 -
PARMA, Italy and BOSTON and CARMIEL, Israel, February 24th, 2023 – Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by...
Rare Disease Day
Today there are still many people who are completely unaware of the rare diseases’ world. For this reason, since 2008, the Rare Disease Day has been celebrated with the aim of spreading awareness on rare diseases and fighting for achieving healthcare equity for all the people living with a...
What does it mean to be a B Corp? Chiesi's choice for a sustainable future
Since 2017, March has been ‘B Corp Month’, dedicated to celebrating and raising awareness of a young, but already established global movement (the B Corp movement), born out of a revolutionary idea: using business as a force for good.
For centuries, our society has been founded...
Chiesi Group and Affibody collaborate to develop and commercialize innovative treatments for respiratory diseases
Chiesi Group and Affibody will collaborate closely to develop novel Affibody® molecules as innovative treatments for respiratory diseases.
This agreement expands Chiesi’s comprehensive R&D program in respiratory diseases with high unmet medical needs.
Affibody will receive an...
#PlaytheRareGame – La campagna di sensibilizzazione sulle malattie rare presente al Sei Nazioni 2023 a Roma!
-
Restore to Impact - The next healthcare landmark for innovation and future-oriented competencies
International Call for ideas for the regeneration of the Chiesi pharmaceutical group's historic industrial site
at Via Palermo, Parma
March 1st – April 30th, 2023
Starting today, Wednesday 1 March, Restore to Impact - The next healthcare landmark for innovation and...
In 2022 Chiesi Group has been confirmed as the 1st Italian pharmaceutical company for the number of patents filed
Once again, Chiesi Group has been confirmed as the 1st Italian pharmaceutical company and the 3rd among the Italian companies in all segments, for patents applications, with a consolidated number of 42 first filings at the European Patent Office (EPO), according to the publication of the patenting...
European Parliament vote on the revision of the EU’s legislative framework on F-gas: climate targets need innovative solutions
Recently, the European Parliament adopted its position on the revision of the EU’s legislative framework on fluorinated greenhouse gases (F-gases) emissions.
Chiesi shares the climate objectives and ambitions of European policymakers and welcomes the robust discussion around the...
2022 for Chiesi: The Group’s international growth continues
Turnover at €2 billion 749 million, with growth of 13.6% over 2021;
The European market remains at the center, with significant international development;
The distribution of turnover by therapeutic area is as follows: Air (respiratory diseases) 73%, Rare (rare and ultra-rare diseases) 12%...
World Health Day: our commitment to provide Health For All
Today, on World Health Day, we celebrate the right to good health for every person, everywhere. The theme for this year's World Health Day is "Health For All: Joining Forces for a Better Future," which highlights the importance of working together to achieve universal health coverage and better...
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc
Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases.
Parma Italy, Dublin Ireland and Boston MA, April 12, 2023 – Chiesi Farmaceutici S.p.A. (“Chiesi”), an...
A behavioral therapy app to close the access gap in COPD treatment
The story behind an exceptional partnership and innovative product
By Ameya Phadke, Patients Non-Pharma Solutions Leader at Chiesi Group
Earlier this year, Kaia COPD, a digital solution aimed at improving the quality of life for COPD patients, has been listed in the...
Chiesi Global Rare Diseases Announces European Commission (EC) Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
Pegylated enzyme replacement therapy designed to provide a long half-life*
Updated August 17, 2023
PARMA, Italy and BOSTON, May 5, 2023 – Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by...
Climate Change Threatens Respiratory Patients' Quality of Life Stretching Beyond Physical Health to Overall Well-Being, New Report Warns
A new survey, part of a report published by Economist Impact and supported by Chiesi, focuses on how respiratory patients experience the adverse effects of poor air quality.
The report, result of a scoping literature review and survey, recognizes that climate-related factors have a significant...
Chiesi Global Rare Diseases Announces FDA Approval of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
Updated August 17, 2023
BOSTON, May 10, 2023 – Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, announced today that the U.S. Food and Drug Administration (FDA) has approved...
Emergenza alluvione in Emilia-Romagna: l’impegno del Gruppo Chiesi
-
LEED certification: Chiesi's commitment for the sustainability of its buildings
Buildings are responsible for a considerable amount of global energy use, resource consumption and greenhouse gas emissions and significantly impact the health of our planet and its inhabitants.
At Chiesi, we strive to improve the sustainability performances of all our sites.
With our...
Chiesi at EPNS 2023 to confirm its commitment on alpha-mannosidosis with the projection of the movie “Rare Land” and the presentation of 4 posters
”Rare Land” is a movie by Eftimiz Hatzis, which gives the audience a front-row seat to understand the difficult experience of a family facing a rare disease, such as alpha-mannosidosis.
Challenges in the early diagnosis of rare and ultra-rare diseases and opportunities to...
Alessandro Chiesi appointed Chair of the Chiesi Group
Maria Paola Chiesi becomes the Vice Chair
Alessandro Chiesi has held the post of Chief Commercial Officer since 2020, and succeeds Alberto Chiesi, who, together with his brother Paolo, led the Group to global expansion over the past five decades.
Parma (Italy), July 7th, 2023 – Chiesi announces the appointment of...
Chiesi's Sustainability Report 2022: a year of tangible achievements for patients, communities, and the planet
Chiesi’s Sustainability Report 2022 is released today;
The company has committed to reaching Net Zero GHG emissions by 2035;
130,000 units of Chiesi medicines, valued at €4.5 million, were donated to patients in conflict territories;
The company closed the gender pay gap at Group...
Chiesi’s 2022 Sustainability Report: “Purpose First”
With the publication of Chiesi's Sustainability Report, Maria Paola Chiesi, Chiesi's Vice Chair and Head of Shared Value & Sustainability, sheds light on the company's sustainability initiatives of the last year and their impact.
Looking back to 2022, what highlights confirm for you...
Inclusiveness, transparency and harmony: Chiesi Group introduces Human Rights Policy
Doing business in harmony with the environment that surrounds us, generating profit and, at the same time, contributing to the creation of shared value for the community, giving a positive push towards a future that really puts people at the centre, emphasising responsibility, transparency and...
Chiesi Group mid-year financial results demonstrate strong growth for 2023
Chiesi Group announces mid-year turnover of €1,497 million;
Substantial growth of each of Chiesi’s business areas;
Europe remains the biggest market, followed by the US and China;
Forecasted revenues of about €3 billion for 2023, with an additional solid growth expected in...
Chiesi Open Day 2023: a day of sharing and discovery
During our first Open Day on Saturday, October 14th we opened the doors of all Chiesi sites in Parma to our dear ones. More than 2,000 people came to visit us and discover the Chiesi way of working and living. It was an extraordinary day!
Fostering a sense of community and family within...
Chiesi Global Rare Diseases Announces Multiple Presentations at SSIEM Annual Symposium 2023
Total of six poster presentations analyze the effects of treatment with enzyme replacement therapies in Fabry disease and alpha-mannosidosis;
Company sponsoring symposium on advances in monitoring and management in Fabry disease.
BOSTON (USA), September 1st, 2023 – Chiesi Global...
Chiesi Group and Statkraft sign a 10-year renewable energy PPA
Chiesi Group and Statkraft, Europe's largest producer of renewable energy, have signed a major agreement to supply more than 30 Gigawatt-hours per year of renewable electricity lasting 10 years starting in 2024.
With this Renewable Power Purchase Agreement (PPA), Chiesi on the one hand...
Chiesi Foundation’s NEST Partners Meeting in Sub-Saharan Africa
For the first time in the Foundation's history, a week of work and meetings with local authorities, hospital directors, doctors and nurses from Burundi, Burkina Faso, Togo, and Benin.
The Foundation is active in the field of international health cooperation, through the transfer of scientific...
Chiesi Global Rare Diseases Releases Report on the Burden of Care for Rare Diseases and Its Economic Impact on European Citizens
New research from Chiesi analyses the economic burden for 23 rare diseases across five therapeutic areas in three EU Member States and will be launched during a panel at the World Orphan Drug Congress (WODC) in Barcelona, Spain.
The panel hosted by Chiesi is titled, ‘Reducing the burden of...
Chiesi Group Partnership Day 2023
The event brings together the company’s key partners to discuss the best practices in terms of quality, service level, innovation, collaboration and Chiesi’s value chain sustainability journey;
The 2023 “Partner Awards” will be dedicated to entities that...
Chiesi Partnership Day 2023
Trust, Future, Sinergy, Resilience. They are just few of the key words around which the definition of partnership was built during the fourth Chiesi Partnership Day. An event dedicated to the celebration and awarding of Chiesi Group’s strategic partners that have distinguished themselves in...
Chiesi Group signed a License Agreement with Haisco Pharmaceutical to develop, manufacture, and commercialise a novel, reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis
Chiesi Group and Haisco Pharmaceutical will collaborate closely to develop HSK31858, a novel reversible dipeptidyl peptidase 1 (DPP1) inhibitor for respiratory diseases.
This agreement expands Chiesi’s comprehensive R&D program in bronchiectasis, a respiratory disease with high...
Chiesi awarded with Great Place to Work™ recertification
Chiesi Group has been officially reaccredited as a Great Place to Work-Certified™ organization in Italy (Headquarters and Chiesi Italy), Australia, Austria & CEE Countries, Benelux, Brazil, Canada, China, France (Chiesi France and NHCO), Germany, Greece, Italy (Chiesi HQ and Chiesi...
Taking a Stand: Our Global Commitment Against Workplace Harassment and Violence
The International Day for the Elimination of Violence Against Women was observed globally on November 25th. To us, it is not merely a date on the calendar; it is a global call to action. It represents an opportunity to keep shedding light on the pervasive issue of gender-based violence that affects...
Chiesi explores the impact of climate change on people living with respiratory conditions in the series “The Climate and Us”
Chiesi Group proudly shares its contribution to the thought-provoking series “The Climate and Us”, presented by the Global Climate and Health Alliance and produced for them by BBC StoryWorks.
The climate crisis is a health crisis1 impacting the health of people around the world...
Restore to Impact | Award Ceremony
Restore to Impact | Award Ceremony
Casa della Musica
Parma
Domusforum 2023
ADI Design Museum
Milan
Restore to Impact Award Ceremony and Domusforum 2023. Two events for a reflection dedicated to the themes of urban regeneration and the future of cities....
Chiesi was awarded the 59° Oscar di Bilancio for the Benefit Corporation category
The company has been awarded for its 2022 Sustainability Report, at Palazzo Mezzanotte in Milan, headquarters of Borsa Italiana.
Parma, December 18, 2023 – Chiesi, a research-oriented international biopharmaceutical group, was awarded the 59th Oscar di Bilancio for the Benefit...
Chiesi Global Rare Diseases Receives FDA Approval for FILSUVEZ® (birch triterpenes) topical gel for the Treatment of Epidermolysis Bullosa
FILSUVEZ topical gel is indicated for the treatment of partial thickness wounds in patients 6 months and older with Junctional and Dystrophic Epidermolysis Bullosa (EB)
FILSUVEZ was well tolerated and met the primary endpoint with statistical significance, with 41.3% of patients achieving first...
Chiesi Group and Oak Hill Bio announce License and Development Agreement to develop, manufacture, and commercialize OHB-607, a potentially transformative neonatal therapy
Chiesi Group and Oak Hill Bio will collaborate closely to develop OHB-607, a clinical-stage investigational drug candidate, to treat complications of extremely premature birth;
This agreement expands Chiesi’s commitment to Neonatology, a highly strategic area for the company;
Partners...
Empowering Women in Science and Healthcare: Chiesi’s Commitment to Gender Equality
In 1936, Neive Terzi became the first female researcher hired at Chiesi, a year after the company was founded as a pioneer in the healthcare field. Not only was she the first employee with a degree at the time, but she laid the foundation of a journey of women empowerment that has become deeply...
PAST, PRESENT, FUTURE
Chiesi Farmaceutici S.p.A.
Via Palermo 26, Parma
16 February — 18 May 2024
“The greatest commitment has been to embrace and respond to change,
quickly adapting to changing internal and external contexts,
and understanding the need for innovation ahead of...
Chiesi Group announces the passing of Honorary President Dr. Paolo Chiesi (1940-2024)
Parma, March 5th, 2024 - Chiesi Group announces the passing of Honorary President Dr. Paolo Chiesi, a fundamental pillar of the company who shaped its history alongside his brother Alberto.
Born in Parma in 1940 and graduating in Chemistry and Pharmacy, he led the Corporate Research and...
Chiesi’s investment in women equal pay achieves the Fair Pay certification
On this International Women's Day Chiesi joins the commitment of the UN for 2024, "Invest in Women: Accelerate Progress," and proudly announces a significant milestone in its dedication to gender equality.
The international biopharmaceutical Group has received top-level certification from...
Chiesi Achieves Platinum Medal from EcoVadis
As a testament to its steadfast commitment to sustainability, Chiesi proudly announces its achievement of the Platinum medal from EcoVadis, with a score of 78/100. This important recognition places the company among the top percentage of organizations assessed by Ecovadis.
EcoVadis...
Chiesi Group: a new supplementary labor agreement in Italy puts people and their needs first
The new agreement covers the three-year period 2024-2026 and applies to over 2,200 people from Chiesi Farmaceutici and Chiesi Italia employed under Italian law.
An innovative labor agreement has been created to include many new elements and improvements related to Inclusivity, Equity, and...
Chiesi Carbon Minimal Inhalers reach new milestone with clinical phase III initiation
Chiesi Group announces a major step in the development of carbon minimal inhalers with the initiation of a new phase III long-term safety trial.
The trial comes after the completion of two short-term clinical safety studies with the new low global warming potential propellant and three clinical...
Chiesi Group's 2023 Revenue Surpasses €3 Billion Mark, Reflecting 10% Growth Year-on-Year (+12% @CER), Underlining Commitment to Innovative, Sustainable Practices
Highlights from Chiesi Group’s 2023 financial report:
Sales increased to over €3 billion, up 10% compared to 2022 (+12% @CER), driven by the Rare business unit growth (65% @CER), and steady growth of all products in all its Regions
24% of 2023 sales were devoted to R&D to create...
Chiesi Farmaceutici S.p.A. has obtained ISO 37001:2016 certification for its Anti-Bribery Management System
Over 70 people involved, more than 20 departments that contributed, ten months of work: these are the numbers behind Chiesi certification.
This certification, obtained through the collaboration of a dedicated cross-functional team, confirms Chiesi’s commitment to operate in accordance with...
Chiesi and Gossamer Bio Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications
Strategic collaboration to leverage Chiesi's legacy of respiratory leadership and Gossamer Bio's development expertise in pulmonary hypertension.
Gossamer to receive $160 million development reimbursement payment and eligible to receive up to $146 million in regulatory and $180 million in sales...
Empowering Diversity & Inclusion: Chiesi Affinity Networks
At Chiesi, we aim to create an inclusive environment and foster a culture where everybody feels valued, respected, and empowered to freely express themselves, making our Company #ThePlaceToBe.
This goal is attainable thanks to the guidance of our Global D&I Vision and Strategy and the support...
Chiesi Group Forges Alliance with Karolinska Institutet to Tackle Urgent Health Challenges
The collaboration is underpinned by a shared commitment to advancing medical science and improving patient care through joint research, development, and innovation efforts
Parma, 14 May 2024 – Chiesi Group, a research-oriented international biopharmaceutical group, proudly announces the...
Oak Hill Bio and Chiesi Group Announce First Patient Enrolled in the Resumed Phase 2b Clinical Study Evaluating OHB-607 for the Prevention of Bronchopulmonary Dysplasia, the Most Common Cause of Chronic Lung Disease in Premature Infants
Design of multi-center study is based on previous Phase 2a clinical data, which showed a decrease in the occurrence of severe bronchopulmonary dysplasia (BPD)
OHB-607 has the potential to be the first innovative respiratory therapeutic advance for extremely preterm neonates in over thirty...
Chiesi to Present Data at the American Thoracic Society Conference
Eight abstracts from Chiesi’s global respiratory research portfolio will be presented at the American Thoracic Society (ATS) 2024 International Conference in San Diego starting from May 17, 2024. Presentations include preclinical and clinical stage global studies in asthma, Chronic...
Bringing Sustainability and Strategy together to create Shared Value: Insights from Chiesi’s 2023 Sustainability Report
Chiesi Group's Sustainability Report 2023 highlights impacts on strategic areas such as Patients, Planet, People and Prosperity while anticipating regulatory changes.
Patients: Chiesi invested 23.8% of its revenues in research and development and advocated for patients with respiratory...
Chiesi Group Unveils Innovations in Respiratory Care, Patient Insights into Decentralization of a Clinical Trial and Developments in Carbon Minimal Inhaler Project at ERS Congress 2024
At the 2024 European Respiratory Society Congress (ERS), Chiesi Group will convene two symposia to highlight the importance of patient centricity in managing asthma and COPD
Chiesi Group will present the value for patients in using innovative decentralized elements in clinical trial...
Code of Interdependence Workshop: a great opportunity for collaboration
Collaboration, co-creation and the exchange of ideas were at the heart of the Code of Interdependence workshop. The event was an opportunity to strengthen the Chiesi Group's strategic collaboration and to promote innovative solutions from the perspective of Chiesi's partners. ...
Chiesi Group’s new Biotech Center of Excellence brings the future of medicine to Parma
Chiesi Group is making a strategic investment of € 400 million to establish its new Biotech Center of Excellence in Parma.
The Center is designed to integrate the entire supply chain, enhancing innovation and production, while its seamless research-production integration will accelerate...
Chiesi Group’s near and long-term science-based emissions reduction targets have been validated by the SBTi
In a significant advancement in its commitment to combating climate change and promoting sustainability, Chiesi Group is proud to announce that the Science Based Targets initiative (SBTi) has validated its near- and long-term science-based emissions reduction targets, establishing a net-zero goal...
Great Place To Work and Fortune Name Chiesi Group No. 23 in 2024 World’s Best Workplaces™ List
Chiesi is the only European pharmaceutical company and the first Italian company ever to be included in the World’s Best Workplaces™
The accolade reflects Chiesi's dedication to people’s well-being, continuous improvement, and creating a positive work environment
Chiesi was...
Chiesi Group Reaffirms Its EcoVadis Platinum Medal
For the second consecutive year, Chiesi Group has been awarded the Platinum Medal by EcoVadis, ranking among the top 1% of companies worldwide for outstanding performance in Environment, Ethics, Labor and Human Rights, and Sustainable Procurement.
This achievement, which reflects a...
Chiesi Group appoints three new independent Non-Executive Directors to its Board, supporting company evolution and growth
Chiesi Group appoints Roch Doliveux, Paolo Pucci, and Daphne Quimi to further enhance Board capabilities and internationalize leadership
These senior business leaders bring diverse expertise and international experience, strengthening governance and international best practices, whilst...
Jefferies Global Healthcare Conference
June 3rd – 5th, 2025
CPHI Europe
October 28th- 30th, 2025
Asia Bio Partnering Forum
September 8th –9th, 2025
JP Morgan Healthcare
January 13th-16th, 2025
LSX World Congress USA
September 16th - 17th, 2025
ERS
September 27th – October 1st, 2025
World Orphan Drug Congress Europe
October 27th- 29th, 2025
Embracing Sustainability and Inclusivity: Updated Code of Interdependence
As part of our ongoing commitment to sustainability, Chiesi has updated its Code of Interdependence, aligning it with the latest industry standards and best practices. By focusing on the Sustainable Development Goals (SDGs) where we and our partners can have the greatest impact, we actively...
In Memory of Dr. Paolo Chiesi: Visionary Leader and Innovator
Today marks the one-year anniversary of the passing of Dr. Paolo Chiesi, former Honorary President of Chiesi Group.
Dr. Paolo Chiesi was a visionary leader and a cornerstone of Chiesi Group for almost sixty years. His contributions to scientific progress and innovation have left a lasting impact...
LEED Certification: Sustainable Workspaces for People and the Planet
At Chiesi, we are committed to creating workspaces that prioritize both environmental sustainability and the well-being of those who inhabit them. The company aims to provide buildings that not only minimize their environmental impact but also foster healthy, productive environments for the people...
Chiesi Acquires New Manufacturing Site in Nerviano (Milan) with a Strategic €430 Million Investment To 2030 to Drive Global Growth
The project is part of the Group’s industrial plan to support its global growth
The site will specialize in the production of sterile biological products, DPI and carbon minimal inhalers for the treatment of respiratory diseases, with a primary focus on the latter
The redevelopment of the...
Chiesi Group delivers on transformational strategy with FY2024 double-digit growth (13% at CER), strong investment in innovation and continued focus on sustainability
HIGHLIGHTS
€3.4 billion revenues, up 13% at constant exchange rates (CER) compared to 2023
Record R&D investment of €829 million (24.3% of revenues)
Profitability close to 30% for the fifth consecutive year
Air franchise: revenues of €1.8 billion, a growth of 7.2%% (CER)....
Foster® Spray & Foster® NEXThaler®
It is a fixed combination for inhalation of beclomethasone dipropionate (anti-inflammatory) plus formoterol fumarate (bronchodilator). The spray-formulated product (pMDI, Modulite®) releases extra-fine particles. Foster is also available on the market as a dry powder formulation (DPI) for...
Atimos®
It is a Modulite®-based spray formulation (pMDI) of formoterol fumarate, a long-acting β2 agonist (LABA). Atimos is indicated for the prevention and treatment of the bronchospasm (1-2 puffs twice-daily) in patients with asthma and COPD, in both adults and children over 6 years of age.
Clenil®
The Clenil brand includes a range of beclomethasone-containing products, a corticosteroid, in a variety of formulations indicated for a range of inflammation-driven respiratory diseases, including asthma, allergic rhinitis and bronchostenosis conditions: Clenil Spray (pMDI,...
Peyona®
Peyona® is a caffeine citrate solution, indicated for the treatment of primary apnoea in preterm neonates. It can be administered either by slow intravenous infusion or orally.
Treatment with caffeine citrate should be initiated under the supervision of a physician...
Curosurf®
Curosurf® (poractant alfa) intratracheal suspension is a natural surfactant prepared from porcine lungs. It is administered via the intra-tracheal route in intubated infants undergoing mechanical ventilation for respiratory distress syndrome (RDS).
Curosurf® is indicated...
Trimbow® Spray
Trimbow Spray is a fixed combination of beclomethasone dipropionate (corticosteroid), formoterol fumarate (long acting β2 agonist) and glycopirronyum bromide (long acting muscarinic antagonist). The spray-formulated product (pMDI, Modulite®) releases extra-fine particles. The product is...
